Comparison of the effects of 10.6-μm infrared laser and traditional moxibustion in the treatment of knee osteoarthritis

Lin Lin¹ · Ke Cheng¹² · Ming T. Tan³ · Ling Zhao¹ · Zouqin Huang⁴ · Chang Yao⁵ · Fan Wu¹ · Haimeng Zhang¹ · Xueyong Shen¹²

Received: 12 May 2019 / Accepted: 16 August 2019 / Published online: 24 August 2019
© The Author(s) 2019

Abstract
Based on two separate randomized controlled trials (RCTs) on traditional Chinese medicine (TCM) moxibustion and 10.6-μm infrared laser moxibustion in treating knee osteoarthritis (OA), we did an indirect and preliminary comparison of the effects of the 10.6-μm laser moxibustion with the traditional moxibustion for knee osteoarthritis. The objective was to see whether the laser moxibustion is non-inferior to the traditional moxibustion in alleviating symptoms of knee osteoarthritis such as pain, stiffness, and joint dysfunction as well as improving quality of life for the patients with knee osteoarthritis, and whether a further RCT directly comparing the laser and traditional moxibustion is necessary. Pooled data from two RCTs in patients with knee osteoarthritis, trial ISRCTN68475405 and trial ISRCTN26065334, were used. In the two RCTs, the eligibility criteria were almost identical, the treatment procedure (i.e., sessions, duration, and points) were similar, and the outcome measurements (i.e., WOMAC for symptoms and SF-36 for quality of life) were the same. The double robustness method was used for the WOMAC scale and the SF-36 endpoints to detect the difference between traditional and laser moxibustion. The analysis comprised 55 patients from ISRCTN68475405 in real moxibustion arm (moxibustion group) and 88 patients from ISRCTN26065334 in real laser moxibustion arm (laser group). Demographic characteristics and course of disease were similar between the two groups. Causal inference, using the doubly robust estimating approach to correct for bias due to baseline differences, showed that there was no statistically significant difference in the WOMAC pain, stiffness, and physical function between the two treatments at midterm, end of treatment, and 4 weeks after the end of treatment (P > 0.05). The exception was that there was statistically significantly more benefit associated with laser moxibustion compared with traditional moxibustion in physical function at the follow-up of 4 weeks after the end of treatment (P = 0.006). There was no statistically significant

Lin Lin and Ke Cheng contributed equally to this study, and should be considered as co-first authors.

Ke Cheng
cheng_ker@hotmail.com

Xueyong Shen
sxy1@shutcm.edu.cn

Lin Lin
527116245@qq.com

Ming T. Tan
mtt34@georgetown.edu

Ling Zhao
zl2@shutcm.edu.cn

Zouqin Huang
hzmusic@yeah.net

Chang Yao
yaochang123456@sina.com

Fan Wu
lunchwf@hotmail.com

Haimeng Zhang
haimengzhang@126.com

¹ School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, 1200 Cailun Road, Shanghai 201203, China

² Shanghai Research Center of Acupuncture & Meridians, Shanghai 201203, China

³ Department of Biostatistics, Bioinformatics & Biomathematics, Georgetown University Medical Center, Washington, D.C. 20057, USA

⁴ Shanghai Pudong New Area Hospital of Traditional Chinese Medicine, Shanghai 201299, China

⁵ Zhongshan Hospital of Zhejiang Province, Hangzhou 310005, Zhejiang Province, China
difference in most SF-36 endpoints \( (P > 0.05) \) except that physical functioning (PF), mental health (MH), and bodily pain (BP) were statistically significantly better in the laser group than in the traditional moxibustion group at the follow-up of 4 weeks after the end of treatment \( (P = 0.005, 0.034, 0.002) \). The benefits of 10.6-\( \mu \)m infrared laser moxibustion and the traditional moxibustion for knee osteoarthritis were comparable in pain, stiffness, physical dysfunction, and in most of the quality of life subdimensions. The laser moxibustion might be more beneficial in terms of physical function, body pain, and mental health in the long term. RCTs directly comparing 10.6-\( \mu \)m laser moxibustion with traditional moxibustion are warranted.

**Keywords** Laser · Acupuncture · Moxibustion · Knee osteoarthritis · Clinical trial

## Introduction

Osteoarthritis is a common degenerative disease, and the knee is one of the most commonly affected joints [1]. Knee osteoarthritis mainly manifests symptoms such as pain stiffness, swelling, and dysfunction of the knee joints, which greatly affect the quality of life of the patient. A survey showed that, among the world’s population aged 60 years or older, 18% of the females and 9.6% of the males have osteoarthritic symptoms [2]. In China, the incidence of osteoarthritis is 3–9% [3]. There are currently no known cures for knee osteoarthritis. Guidelines for the osteoarthritic treatments aim at relieving pain, maintaining or improving joint functions, as well as improving the quality of life of the patients [4]. Non-surgical therapies include pharmacological and non-pharmacological treatments. The pharmacological treatments mainly are analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), and intra-articular injection of medicine, etc. Non-pharmacological treatments include lifestyle changes, weight loss, and low-intensity aerobic exercises. Surgery can be considered when systematic conservative treatments fail to relieve pain and the knee joint function is severely affected. NSAIDs have been widely used to relieve knee pain and stiffness. However, the use of NSAIDs is substantially limited by their side effects, especially those that occur after long-term use, including gastric ulcers, gastrointestinal bleeding, and kidney damage [5–7]. It has been reported that 50% of the patients with chronic knee pain failed to achieve acceptable pain relief through medication, and most of those patients had sought complementary therapies, including traditional Chinese acupuncture and moxibustion [8, 9].

Moxibustion, a traditional Chinese medicine method with moxa burning over the acupuncture points, is commonly used to treat knee pain due to osteoarthritis, and is often used with needle acupuncture to achieve better effects. The heat produced by the burning moxa is believed to be an essential factor in achieving therapeutic effect. Clinical studies and systematic reviews showed that traditional moxibustion was associated with relieving pain and improving physical function and quality of life in patients with knee osteoarthritis [10–15]. Like needle acupuncture, moxibustion avoids gastrointestinal, renal, cardiac, and hematological side effects which are common in conventional pharmacological treatment [16]. However, the burning moxa produces an annoying smoke and smell, which is irritating and might be harmful to both the patients and practitioners [17, 18] and might limit the use of moxibustion in the clinic.

Our previous studies found that the infrared radiation spectra produced by traditional moxibustion are similar with that of the acupoints, and both peaks locate at around 10 \( \mu \)m. In this way, traditional moxibustion might induce resonance absorption and exert its therapeutic effect. CO\(_2\) laser is a far-infrared laser with the wavelength of 10.6 \( \mu \)m, which is close to the peak of infrared radiation spectrum of the traditional moxibustion and human acupoints. CO\(_2\) laser can be absorbed within 0.2 mm of the epidermis and produce a fast, marked, and lasting thermal effect on the skin surface [19, 20] like traditional moxibustion. Thus, we assume CO\(_2\) laser might be a good substitute for the traditional moxibustion due to its advantages of producing similar thermal effects and causing no smoke nor smell.

So far, the comparison of the effects of CO\(_2\) laser moxibustion and the traditional moxibustion has not yet been reported. In this study, by using the available data in two independent randomized controlled trials (RCTs), we did an indirect and preliminary comparison of the effects of 10.6-\( \mu \)m laser moxibustion and traditional laser moxibustion in the treatment of knee osteoarthritis. The purpose was to see whether the 10.6-\( \mu \)m CO\(_2\) laser moxibustion would have a similar effect as the traditional laser moxibustion in alleviating symptoms and improving quality of life for patients with knee osteoarthritis, and whether a further head-to-head RCT comparing the laser moxibustion and traditional moxibustion is necessary. This hypothesis was based on the primary outcomes (WOMAC pain and function at the end of treatment) in two separate trials (i.e., the ISRCTN68475405 trial and the ISRCTN26065334 trial). In the ISRCTN68475405 trial, the percentage of improvement in WOMAC pain and function was 60.5% and 54.4% respectively in the true moxibustion group at the end of treatment, which was significantly higher than that in the sham moxibustion group; while in the ISRCTN26065334 trial, the percentage of improvement in WOMAC pain and function were 57.5% and 54.9% respectively in CO\(_2\) laser group, which were also statistically significantly higher than that in sham laser group. The improvement of pain and function in both the laser and traditional moxibustion groups reached the clinical
success rate (i.e., at least 36% improvement in WOMAC score) [21], and were also similar. Thus, it was expected that the effectiveness of 10.6-μm CO₂ laser moxibustion may be similar to that of traditional moxibustion, and could be a smoke-free substitute for the traditional moxibustion in treating knee OA.

Patients and methods

Patients

An exploratory analysis was performed using pooled data from two trials: (1) A randomized double-blinded controlled trial was undertaken to compare the efficacy of traditional Chinese moxibustion to that of sham moxibustion in patients with knee osteoarthritis, clinical trial registration number: ISRCTN68475405. (2) A randomized double-blinded controlled trial was conducted to compare the efficacy of infrared CO₂ laser moxibustion to that of sham laser in treating knee osteoarthritis, clinical trial registration number: ISRCTN26065334 (Fig. 1). We had full access to the data of both RCTs. The two RCTs had almost identical eligibility criteria, and participants were included only if they (1) were diagnosed with idiopathic knee OA according to the American Rheumatism Association (ARA) classification criteria [22]; (2) experienced moderate or severe knee pain on most days of the past month; (3) aged 42–80 years old, no limit on gender; (4) were on X-ray revealed evidence of knee osteoarthritis (Kellgren-Lawrence grade ≥ 2; Kellgren Lawrence grading scale: grade 0, normal; grade 1, doubtful narrowing of joint space and possible osteophytic lipping; grade 2, definite osteophytes, definite narrowing of joint space; grade 3, moderate multiple osteophytes, definite narrowing of joints space, some sclerosis and possible deformity of bone contour; grade 4, large osteophytes, marked narrowing of joint space, severe sclerosis, and definite deformity of bone contour [23]); (5) were willing to refrain from changing the medication regimen during the trial. The patients were not permitted to continue to take steroidal drugs but were permitted to continue to use NSAIDs and other drugs, if they had already been using them before the trial; (6) had not undergone acupuncture, moxibustion, or paste treatment on the knee areas during the past 3 months; and (7) were willing to comply with treatment arrangements and understand and sign the informed consent form. The two RCTs also had almost identical exclusion criteria: patients were excluded if they (1) were diagnosed with inflammatory arthritis, gout, acute knee joint injury, other knee arthritis (without cartilage involvement), meniscus injury, ligament injury, or intra-articular fracture; (2) had serious heart, kidney, or liver disease, malignant tumors (unless the patient was surgically treated, and had no relapse for more than 5 years), systemic infections, or contagious diseases; (3) were receiving intra-articular corticosteroid or hyaluronate injections; or other external treatment like topical use of medication in the preceding 6 months, or had previous history of knee surgery; and (4) were recruited in other clinical trial simultaneously or previously used trial drug for KOA.

Treatment

In ISRCTN26065334, an SX10-C1 infrared laser moxibustion instrument developed by the Shanghai University of Traditional Chinese Medicine and the Shanghai Wanqi Optical Technology Ltd. was used to treat the patients in laser moxibustion group (Fig. 2). The wavelength of the infrared laser was 10.6 μm; the output power was set between 160 and 180 mW; energy density ranged from 61.2 to 68.8 J/cm² for one treatment; the distance between the defocus probe of the laser and the skin was about 2 cm, and the light spot was 2 cm in diameter on the skin. The patients were told to lie down on their backs and the knee joint was exposed entirely. The acupuncture points that were irradiated were the bilateral ST35 (Dubi) at the knee joint. The patients received a total of 12 sessions of treatments over 4 weeks with 3 sessions a week, and the treatment was given once every other day and lasted 20 min for each session.
In ISRCTN68475405, a stick-on moxa cone was used in the traditional moxibustion group patients (Fig. 3). The stick-on moxa cone consisted of a moxa cone (1.8 cm in diameter) and a cylindrical base (8 mm high). The patients were told to either lie on their backs or sit in a position that would leave both knee joints completely exposed. Three points (ST35 Dubi, EX-LE4 Neixiyan, and Ashi point) were stimulated bilaterally in the treatment. The moxa cones were ignited after being attached to the acupoints. When the patients felt burning at the skin, the moxa cone was removed and a new one would be attached and ignited again. All points received 3 cones in each session. Each patient received a total of 18 treatments over 6 weeks with 3 sessions a week, and the treatment was also given once every other day.

Outcome measurement

The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to evaluate the condition of patients with osteoarthritis of the knee, including pain, stiffness, and physical functioning of the joints [24]. The WOMAC measures five items for pain, two for stiffness, and 17 for functional limitation. Each item is scored by the patients on a 100-mm visual analogue scale (from 0 = no symptoms to 100 = very severe) to assess the pain, stiffness, and physical functioning of their knee joints. The Short Form 36 (SF-36) component was used to evaluate the quality of life of the patients [25]. The survey consists of 36 questions covering eight dimensions including physical functioning (PF), role-physical (RP), role-emotional (RE), bodily pain (BP), vitality (VT), social functioning (SF), mental health (MH), and general health (GH). Each dimension is scored from 0 to 100, with higher scores indicating better condition. The outcomes were measured at baseline, midterm (2 weeks in ISRCTN26065334, 3 weeks in ISRCTN68475405), end of treatment (4 weeks in ISRCTN26065334, 6 weeks in ISRCTN68475405), and 4 weeks after the end of treatment (8 weeks in ISRCTN26065334, 12 weeks in ISRCTN68475405).

Statistical analysis

The primary analysis was the comparison of WOMAC score and SF-36 score at the end of treatment. Differences were considered statistically significant at a $P$ value less than 0.05. All numerical data that followed the normal distribution were expressed as mean ± standard deviation (SD); data that did not conform to the normal distribution were expressed as median and quartile range (IQR). For the demographic data, the differences in gender and affected joints between the groups were analyzed using chi-square test, and the numerical data were analyzed with $t$ test.

To estimate the causal effect of 10.6-μm laser moxibustion treatment from external control (observational data), i.e., where patients are not randomized into treatment and control, it is important to account for potential confounding factors, and this corrects for the bias due to baseline differences between groups. Currently, there are mainly three approaches for causal inferences which give unbiased estimates of the treatment effects when one is willing to assume no unmeasured confounders. The first is the regression modeling of outcome WOMAC score with different baseline covariates. The second is the inverse propensity score weighting where the propensity score is obtained with a statistical model of the probability of a patient being assigned to treatment or control given the baseline covariates. Both approaches depend on correct specification of the model. The more recent approach is the doubly robust estimate approach which combines the regression
modeling and the inverse propensity score weighting approaches in a fortuitous way by a weighted sum of the estimators from regression and from propensity model. It has been shown the treatment effect estimates are unbiased even when only one of the models, either regression or propensity model, is correctly specified. It offers protection against incorrect model assumptions, thus leading to more precise inferences [26, 27]. Therefore, we have chosen the doubly robust approach for our analysis of the causal effect of the treatment. The double robustness method is used for the WOMAC scale and the SF-36 endpoints. The computation is implemented in R. The causal corrected $P$ value for each of the two endpoints is reported. The $P$ values reported are not adjusted for any multiple comparisons.

### Results

#### Patient characteristics

In ISRCTN26065334 trial, 178 patients were enrolled from the Shanghai Longbai Community Health Service Center from August 2010 to September 2011. Eighty-eight patients were randomly assigned to the laser group and 90 patients to the sham laser group. Four patients were excluded from this analysis, because they withdrew from the treatment due to personal reasons irrelevant to the trial. In ISRCTN68475405 trial, 110 patients were enrolled from the Pudong New Area Chuansha Community Health Service Center from June 2010 to May 2012. Fifty-five patients were randomly assigned to the real moxibustion group and 55 patients to the sham moxibustion group. All patients in the real moxibustion group were included in this analysis. In total, 84 patients in ISRCTN26065334 trial and 55 patients in ISRCTN68475405 trial were included in the present analysis (Fig. 1). Demographic characteristics and basic baseline characteristics such as the affected knee(s) and length of knee OA were similar between the two groups (Table 1).

#### Comparison of the WOMAC score between 10.6-μm laser and traditional moxibustion groups

The raw WOMAC scores of the laser and traditional moxibustion group over time are shown in Table 2. There were

### Table 1 Demographic characteristics and baseline characteristics

| Characteristics                              | Laser moxibustion ($n = 84$) | Traditional moxibustion ($n = 55$) | $P$ value |
|----------------------------------------------|------------------------------|------------------------------------|-----------|
| Age (mean (SD), yrs)                         | $61.25 \pm 5.55$             | $64.73 \pm 6.92$                   | 0.086     |
| No. (% of woman)                             | $66 (78.6\%)$                | $39 (70.9\%)$                      | 0.304     |
| Affected knees (%)                           |                              |                                    |           |
| Single knee                                  | $10 (11.9\%)$                | $10 (18.2\%)$                      | 0.302     |
| Both knees                                   | $74 (88.1\%)$                | $45 (81.8\%)$                      |           |
| Length of knee OA (median (IQR), yrs)        | $6.5 (0.17, 7.75)$           | $5 (0.25, 8)$                      | 0.120     |
| BMI (mean (SD), kg/m$^2$)                    | $25.34 \pm 4.44$             | $24.22 \pm 2.60$                   | 0.231     |

*BMI*, body mass index; *IQR*, interquartile range; *No.*, number; *OA*, osteoarthritis; *SD*, standard deviation; *yrs*, years

### Table 2 Severity of symptoms (WOMAC index scores) over time according to group

| WOMAC index | Time point     | Laser moxibustion ($n = 84$) | Traditional moxibustion ($n = 55$) | $P$ value $^\dagger$ |
|-------------|---------------|------------------------------|------------------------------------|---------------------|
| Pain        | Baseline      | $230.71 \pm 93.18$           | $336.62 \pm 117.38$                | $<0.001$            |
|             | Mid-term      | $143.33 \pm 84.89$           | $239.93 \pm 123.51$                |                     |
|             | End of treatment | $90 (48.5, 143.75)$      | $130 (70, 218)$                    |                     |
|             | Follow-up     | $63.5 (29.5, 119.75)$        | $110 (48, 200)$                    |                     |
| Stiffness   | Baseline      | $97.24 \pm 49.57$           | $45.14 \pm 25.24$                  | $<0.001$            |
|             | Mid-term      | $53 (24.5, 92)$             | $26 (15.5, 45.5)$                  |                     |
|             | End of treatment | $44.40 \pm 33.60$    | $18 (11, 32)$                      |                     |
|             | Follow-up     | $32 (10, 54.75)$            | $15 (6, 30)$                       |                     |
| Function    | Baseline      | $725.53 \pm 345.98$         | $568.96 \pm 261.29$                | 0.005               |
|             | Mid-term      | $477.20 \pm 288.18$         | $375.73 \pm 243.71$                |                     |
|             | End of treatment | $299 (176.75, 531.50)$   | $216 (117, 395)$                   |                     |
|             | Follow-up     | $226 (112.5, 425.75)$       | $191 (106, 329)$                   |                     |

*Data that conform to the normal distribution are presented as mean $\pm$ SD, otherwise they are presented as median (IQR)

$^\dagger P$ values were only presented for the comparison of baseline between the two groups
statistically significant differences between the two groups in the three WOMAC indexes for pain, stiffness, and function at baseline (Table 2). The unadjusted and adjusted difference of the percentage of change from baseline between the two groups over time is shown in Table 3. The results showed that there was no statistically significant difference between laser and traditional moxibustion in WOMAC pain, stiffness, and physical function at almost all time points (\( P > 0.05 \)), except that there was statistically significantly more benefit (i.e., 23.1% more improvement in adjusted estimate) associated with laser moxibustion compared with traditional moxibustion in physical function at the follow-up after end of treatment (\( P = 0.006 \)).}

The raw SF-36 scores of the laser and traditional moxibustion group over time are shown in Table 4. There were statistically significant differences between the two groups in five of the eight SF-36 dimensions, including PF (physical functioning), MH (mental health), SF (social functioning), BP (bodily pain), and GH (general health), at baseline (Table 2). The unadjusted and adjusted difference of the change from baseline between the two groups over time is shown in Table 5. There was no significant difference in all dimensions of SF-36 between the two groups at midterm or at end of treatment. Statistically significant benefits were only found to be associated with laser moxibustion compared to traditional moxibustion in three dimensions including PF (physical functioning), MH (mental health), and BP (bodily pain) at the follow-up after end of treatment (\( P = 0.005, 0.034, 0.002 \)).

**Discussion**

This is a preliminary nonrandomized study comparing the new laser and traditional moxibustion treatments for knee osteoarthritis using available data from two independent RCTs. We found that the analysis shows the laser moxibustion in improving health and possible harm of the new treatment relative to the conventional one. In addition, the results of the analysis would help to conduct a further RCT to evaluate the specific effect size and possible harm of the new treatment relative to the conventional one. Finally, since the sample size for the future RCT would help us determine the sample size for the future RCT, we would need to conduct a further RCT to evaluate the specific effect size and possible harm of the new treatment relative to the conventional one. In addition, the results of the analysis would help to conduct a further RCT to evaluate the specific effect size and possible harm of the new treatment relative to the conventional one. Finally, since the sample size for the future RCT would help us determine the sample size for the future RCT.

This is a preliminary nonrandomized study comparing the new laser and traditional moxibustion treatments for knee osteoarthritis using available data from two independent RCTs. We found that the analysis shows the laser moxibustion in improving health and possible harm of the new treatment relative to the conventional one. In addition, the results of the analysis would help to conduct a further RCT to evaluate the specific effect size and possible harm of the new treatment relative to the conventional one. Finally, since the sample size for the future RCT would help us determine the sample size for the future RCT, we would need to conduct a further RCT to evaluate the specific effect size and possible harm of the new treatment relative to the conventional one. Finally, since the sample size for the future RCT would help us determine the sample size for the future RCT.

### Table 3

| WOMAC index (percentage of change from baseline, %) | Time point | Laser moxibustion (\( n = 84 \)) (%) | Traditional moxibustion (\( n = 55 \)) (%) | Naïve estimate of treatment effect\(^1\) (%) | Doubly robust causal treatment effect\(^2\) (%) | \( P \) value\(^3\) |
|---------------------------------------------------|------------|-------------------------------------|------------------------------------------|--------------------------------------------|---------------------------------------------|------------------|
| Pain                                              | Mid-term   | -32.62 ± 41.15                      | -24.65 ± 43.42                           | -8.0                                       | -7.5                                        | 0.222            |
|                                                  | End of treatment | -47.66 ± 46.37                      | -52.87 ± 31.57                           | 5.2                                        | 2.9                                         | 0.383            |
|                                                  | Follow-up  | -57.57 ± 46.59                      | -57.90 ± 31.77                           | 0.3                                        | 10.1                                        | 0.298            |
| Stiffness                                         | Mid-term   | -28.55 ± 49.32                      | -13.32 ± 69.19                           | -15.2                                      | -15.2                                       | 0.087            |
|                                                  | End of treatment | -42.28 ± 56.45                      | -38.28 ± 52.71                           | 4.0                                        | 3.1                                         | 0.396            |
|                                                  | Follow-up  | -53.99 ± 45.17                      | -45.44 ± 46.92                           | -8.6                                       | -8.0                                        | 0.217            |
| Function                                          | Mid-term   | -28.88 ± 47.46                      | -21.71 ± 79.25                           | -7.2                                       | -7.1                                        | 0.279            |
|                                                  | End of treatment | -41.43 ± 49.30                      | -39.03 ± 71.26                           | -2.4                                       | -2.9                                        | 0.403            |
|                                                  | Follow-up  | -55.95 ± 37.91                      | -50.84 ± 43.67                           | -5.1                                       | 23.1                                        | 0.006            |

\(^1\) Percentage of change of WOMAC index (%; the lower the better) = (post-treatment - baseline)/baseline × 100%

\(^2\) Naïve estimate of treatment effect: unadjusted estimate of treatment effect using original data, i.e., the difference of the percentage of change from baseline between the two groups (change % laser moxibustion - change % traditional moxibustion)

\(^3\) Doubly robust causal treatment effect: adjusted estimate of the treatment effect using double robust causal estimation

\(^4\) \( P \) values for comparing the two groups using doubly robust causal inference approach

The unadjusted and adjusted difference of the percentage of change from baseline between the laser and traditional moxibustion groups in WOMAC pain, stiffness, and physical function at the follow-up after end of treatment.
provide the basis in developing an optimal treatment protocol for the future RCT and future practice.

This exploratory and preliminary comparison found that after correcting for the bias due to baseline between group differences, the effects of 10.6-μm laser moxibustion and traditional moxibustion on pain, stiffness, and physical function were comparable; except that at the follow-up, the laser moxibustion treatment showed more benefit on WOMAC physical function than the traditional moxibustion. As for quality of life, the two treatments showed similar effects on the eight dimensions of SF-36, except that at the follow-up of the treatment, the laser moxibustion treatment showed better effects on PF (physical functioning), MH (mental health), and BP (bodily pain) than the traditional moxibustion. The two groups seemed to be comparable in demographic characteristics, and in most basic baseline characteristics, the most apparent difference was in the treatment protocol. Therefore, a question might be raised whether the benefit of the laser moxibustion was attributed to the difference between the treatment protocols. The fact is that the laser moxibustion protocol consists of less and shorter treatments, as well as less acupuncture points compared to the traditional moxibustion protocol (i.e., one point and 12 sessions over 4 weeks in laser moxibustion protocol versus three points and 18 sessions over 6 weeks in traditional moxibustion protocol). Therefore, we hypothesize laser moxibustion might be at least non-inferior to traditional moxibustion if the same treatment protocol is applied, and might benefit more in the maintenance of the long-term effects. Also, compared with traditional moxibustion, laser moxibustion might have advantages in manipulation, since it would be easier and safer to operate and control with adjustable parameters than supervising the burning moxibustion.

Table 4 Quality of life (SF-36 scores) over time according to group

| SF-36 dimensions       | Time point     | Laser moxibustion (n = 84) | Traditional moxibustion (n = 55) | P value* |
|------------------------|----------------|----------------------------|----------------------------------|---------|
| PF (physical functioning) | Baseline       | 60 (40, 70)                | 60 (45, 70)                       | 0.713   |
|                        | Mid-term       | 65 (50, 80)                | 62.5 (50, 70)                     |         |
|                        | End of treatment | 67.5 (55, 80)            | 65 (53.75, 75)                    |         |
|                        | Follow-up      | 70 (56.25, 80)            | 60 (53.75, 71.25)                 |         |
| RP (role-physical)     | Baseline       | 0 (0, 50)                  | 25 (0, 56.25)                     | 0.140   |
|                        | Mid-term       | 25 (0, 75)                 | 37.5 (0, 100)                     |         |
|                        | End of treatment | 25 (0, 50)               | 25 (0, 75)                        |         |
|                        | Follow-up      | 25 (0, 75)                 | 25 (0, 75)                        |         |
| RE (role-emotional)    | Baseline       | 33.33 (0, 100)            | 33.33 (0, 100)                    | 0.152   |
|                        | Mid-term       | 33.33 (0, 100)            | 66.67 (0, 100)                    |         |
|                        | End of treatment | 33.33 (0, 100)         | 66.67 (0, 100)                    |         |
|                        | Follow-up      | 33.33 (0, 100)            | 33.33 (0, 100)                    |         |
| VT (vitality)          | Baseline       | 45 (30, 55)                | 55 (40, 65)                       | 0.006   |
|                        | Mid-term       | 45 (65, 60)                | 55 (45, 60)                       |         |
|                        | End of treatment | 50 (40, 60)              | 60 (45, 70)                       |         |
|                        | Follow-up      | 50 (35, 65)                | 60 (45, 70)                       |         |
| MH (mental health)     | Baseline       | 64 (48, 79)                | 72 (64, 84)                       | 0.002   |
|                        | Mid-term       | 64 (52, 76)                | 72 (60, 80)                       |         |
|                        | End of treatment | 64 (56, 75)              | 68 (60, 76)                       |         |
|                        | Follow-up      | 68 (60, 80)                | 64 (56, 80)                       |         |
| SF (social functioning) | Baseline       | 75 (62.5, 87.5)           | 75 (62.5, 100)                    | 0.039   |
|                        | Mid-term       | 75 (62.5, 87.5)           | 75 (62.5, 87.5)                   |         |
|                        | End of treatment | 75 (62.5, 84.38)         | 75 (62.5, 87.5)                   |         |
|                        | Follow-up      | 75 (62.5, 87.5)           | 75 (62.5, 87.5)                   |         |
| BP (bodily pain)       | Baseline       | 55 (35, 59.38)            | 67.5 (45, 67.5)                   | <0.001  |
|                        | Mid-term       | 57.5 (45, 67.5)           | 67.5 (55, 67.5)                   |         |
|                        | End of treatment | 67.5 (55, 67.5)         | 67.5 (57.5, 77.5)                 |         |
|                        | Follow-up      | 67.5 (57.5, 75)           | 67.5 (55, 77.5)                   |         |
| GH (General Health)    | Baseline       | 35 (30, 50)                | 50 (35, 60)                       | 0.001   |
|                        | Mid-term       | 40 (30, 55)                | 45 (35, 55)                       |         |
|                        | End of treatment | 40 (31.25, 55)           | 55 (35, 65)                       |         |
|                        | Follow-up      | 45 (35, 58.75)            | 50 (45, 65)                       |         |

*P values were only presented for the comparison of baseline between the two groups.
Table 5  Causal inference using the doubly robust estimating approach to correct for bias due to baseline differences in SF-36 scores between laser and traditional moxibustion treatments

| SF-36 dimensions (change from baseline) | Time point       | Laser moxibustion (n = 84) | Traditional moxibustion (n = 55) | Naïve estimate of treatment effect† | Doubly robust causal treatment effect‡ | P value§   |
|----------------------------------------|------------------|-----------------------------|-----------------------------------|-------------------------------------|----------------------------------------|-----------|
| PF (physical functioning)              | Mid-term         | 6.49 ± 17.11                | 3.45 ± 13.01                      | 3.034                               | 1.255                                  | 0.370     |
|                                        | End of treatment | 9.82 ± 18.34                | 6.27 ± 18.21                      | 3.549                               | 3.305                                  | 0.212     |
|                                        | Follow-up        | 12.14 ± 16.52               | 4.27 ± 19.40                      | 7.870                               | 9.423                                  | 0.005     |
| RP (role-physical)                     | Mid-term         | 14.58 ± 39.43               | 10.00 ± 49.91                     | 4.583                               | 6.051                                  | 0.236     |
|                                        | End of treatment | 5.95 ± 37.35                | 5.45 ± 49.46                      | 0.498                               | 7.857                                  | 0.280     |
|                                        | Follow-up        | 12.20 ± 42.07               | 5.00 ± 44.46                      | 7.202                               | 4.165                                  | 0.370     |
| RE (role-emotional)                    | Mid-term         | 11.91 ± 45.89               | 6.67 ± 42.26                      | 5.238                               | 7.714                                  | 0.302     |
|                                        | End of treatment | 7.14 ± 48.01                | 0.00 ± 56.29                      | 7.143                               | -2.870                                 | 0.409     |
|                                        | Follow-up        | 10.32 ± 17.42               | -0.61 ± 47.79                     | 10.924                              | 15.492                                 | 0.109     |
| VT (vitality)                          | Mid-term         | 2.38 ± 15.55                | 2.09 ± 14.16                      | 0.290                               | -2.794                                 | 0.205     |
|                                        | End of treatment | 7.08 ± 15.05                | 4.82 ± 17.16                      | 2.265                               | 2.799                                  | 0.208     |
|                                        | Follow-up        | 6.79 ± 17.78                | 5.09 ± 20.13                      | 1.695                               | 1.180                                  | 0.373     |
| MH (mental health)                     | Mid-term         | 0 (<8, 12)                  | -3.42 ± 14.49                     | 5.037                               | 5.059                                  | 0.076     |
|                                        | End of treatment | 0 (<8, 12)                  | -4.15 ± 17.82                     | 6.336                               | 5.879                                  | 0.063     |
|                                        | Follow-up        | 3.95 ± 16.15                | -5.31 ± 20.81                     | 9.261                               | 8.746                                  | 0.034     |
| SF (social functioning)                | Mid-term         | 0.45 ± 19.25                | -0.91 ± 20.25                     | 1.356                               | 0.613                                  | 0.445     |
|                                        | End of treatment | 1.79 ± 22.05                | -0.23 ± 19.62                     | 2.013                               | 2.273                                  | 0.288     |
|                                        | Follow-up        | 2.53 ± 20.05                | -3.18 ± 23.10                     | 5.712                               | -2.429                                 | 0.423     |
| BP (bodily pain)                       | Mid-term         | 7.68 ± 15.31                | 4.50 ± 14.44                      | 3.179                               | 0.375                                  | 0.461     |
|                                        | End of treatment | 12.17 ± 19.47               | 8.14 ± 17.20                      | 4.036                               | 1.897                                  | 0.309     |
|                                        | Follow-up        | 16.01 ± 18.79               | 4.32 ± 20.46                      | 11.694                              | 13.587                                 | 0.002     |
| GH (general health)                    | Mid-term         | 3.81 ± 14.64                | -1.91 ± 12.11                     | 5.719                               | 4.606                                  | 0.132     |
|                                        | End of treatment | 4.58 ± 13.56                | 3.91 ± 16.24                      | 0.674                               | -1.658                                 | 0.312     |
|                                        | Follow-up        | 6.37 ± 14.21                | 1.73 ± 17.75                      | 4.642                               | 5.481                                  | 0.168     |

† Change of SF-36 score (the higher the better) = post-treatment – baseline
‡ Naïve estimate of treatment effect: unadjusted estimate of treatment effect using original data, i.e., the difference of percentage of change from baseline between the two groups (change laser moxibustion – change traditional moxibustion)
§ Doubly robust causal treatment effect: adjusted estimate of the treatment effect using double robust causal estimation
§§ P values for comparing the two groups using doubly robust causal inference approach
There are some weaknesses in the study design. First, the available data came from two independent trials. That is, the participants were not randomly assigned to the treatment and control being compared, which introduced the risk that unmeasured confounders would bias the study’s conclusions. Given the defect, we used double robustness method to account for potential confounding factors and corrected for the bias due to baseline differences between groups. Second, the treatment protocol in the two RCTs was different in the number of acupoints, number of sessions, and treatment duration, which limits the internal validity of the results. To provide more convincing clinical evidence for using laser moxibustion, RCTs directly comparing 10.6-μm laser moxibustion with traditional moxibustion, and with sound methodology and large sample size are warranted.

Conclusion

The 10.6-μm laser moxibustion and the traditional moxibustion may result in similar effects in relieving pain, stiffness, and physical dysfunction and in improving quality of life in knee OA patients. The laser moxibustion may be associated with increased benefit for physical function, body pain, and mental health in the long term. RCTs directly comparing 10.6-μm laser moxibustion with traditional moxibustion are warranted.

Funding information

This study partially supported by National Basic research program of China (2015CB554505), Shanghai Technology and Science Commission Fund Project (15401932600), Shanghai Key Laboratory of acupuncture mechanism and acupoint function (14DZZ226500), the Three-Year development plan project for Traditional Chinese Medicine of Shanghai Municipal Health Commission (ZY(2018-2020)-CCCX-2001-05), characteristic discipline building projects of clinical TCM acupuncture and moxibustion in Pudong new area (PDZY-2018-0610), and Xinglin Young Talent Program in Shanghai University of Traditional Chinese Medicine.

Compliance with ethical standards

Competing interests

Ke Cheng and Xueyong Shen have had a patent issued for a type of laser therapy apparatus simulating the infrared radiation spectrum of traditional Chinese moxibustion (China Invention Patent ZL 200910056991.4; issued December 1, 2010).

Abbreviations

RCT, randomized controlled trial; OA, osteoarthritis; NSAIDs, non-steroidal anti-inflammatory drugs; WOMAC, Western Ontario and McMaster Universities’ Osteoarthritis Index; TCM, traditional Chinese medicine

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Dawson J, Linsell L, Zondervan K et al (2004) Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology 43(4):497–504
2. Woollf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81(9):646–656
3. Lv SM, Zhang RL (2016) Research progress in the epidemiology of knee osteoarthritis in middle-aged and elderly patients. Chin J Gerontol (16):4133–4135
4. Agents AI, Effects NS (2010) Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheumatol 43(9):1905–1915
5. Bijlsma JW, Berenbaum F, Lafeber FP (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377(9783):2115–2126
6. Fernandes L, Hagen KB, Bijlsma JW et al (2013) Eular recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 72(7):1125–1135
7. Tramer MR, More RA, Reynolds DJ et al (2000) Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85(1–2):169–182
8. Barnes P, Powell-Griner E, McFann K et al (2002) Complementary and alternative medicine use among adults: United States. CDC Adv Data Rep 2004:343 1–343 34320
9. paramore LC (1997) Use of alternative therapies: estimates from the 1994 Robert wood Johnson Foundation National Access to care survey. J Pain Symptom Manag 13(2):83–89
10. Kim T-H, Kim KH, Kang JW et al (2014) Moxibustion treatment for knee osteoarthritis: a multi-centre, non-blinded, randomised controlled trial on the effectiveness and safety of the moxibustion treatment versus usual care in knee osteoarthritis patients. PLoS One 9(7):e101973
11. Zhao L, Cheng K, Wang L et al (2014) Effectiveness of moxibustion treatment as adjunctive therapy in osteoarthritis of the knees: a randomized, double-blinded, placebo-controlled clinical trial. Arthritis Res Ther 16(3):R133
12. Ren X, Yao C, Wu F et al (2015) Effectiveness of moxibustion treatment in quality of life in patients with knee osteoarthritis: a randomized, double-blinded, placebo-controlled trial. Evidence-based Complement Altern Med: eCAM 2015:569523
13. Song GM, Tian X, Jin YH et al (2016) Moxibustion is an alternative in treating knee osteoarthritis: the evidence from systematic review and meta-analysis. Medicine 95(6):e2790
14. Li A, Wei ZJ, Liu Y et al (2016) Moxibustion treatment for knee osteoarthritis: a systematic review and meta-analysis. Medicine (Baltimore) 95(14):e3244
15. Liu Y, Xu YJ, Lin M (2017) Moxibustion for the treatment of patients with keen osteoarthritis. A systematic review and meta analysis. J Clin Exp Med (08):783–787
16. Mora JC, Przkora R, Cruz-Almeida Y (2018) Knee osteoarthritis: pathophysiology and current treatment modalities. J Pain Res 11:2189–2196
17. Hsu YC, Chao HR, Shih SI (2015) Human exposure to airborne aldehydes in Chinese medicine clinics during moxibustion therapy and its impact on risks to health. J Environ Sci Health A Tox Hazard Subst Environ Eng 50(3):260–271
18. Mo F, Chi C, Gou M et al (2014) Characteristics of selected indoor air pollutants from moxibustion. J Hazard Mater 270:53–60
19. Gaida K, Koller R, Isler C et al (2004) Low level laser therapy—a new model applied to chronic NSAID use. Pain 85(1–2):169–182
20. Li ZM, Zhang ZX (2005) The mechanism on laser acupuncture and moxibustion. Acta Laser Biology Sinica 14(14):8–11
21. Scharf HP, Mansmann U, Streitberger K et al (2006) Acupuncture and knee osteoarthritis: a three-armed randomized trial. Ann Intern Med 145(1):12–20

22. Altman R, Asch E, Bloch D et al (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29(8):1039–1049

23. Kellgren JH, Lawrence JS (1957) Radiological assessment of osteoarthritis. Ann Rheum Dis 16:494–502

24. Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15(12):1833–1840

25. Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483

26. Bang H, Robins JM (2005) Doubly robust estimation in missing data and causal inference models. Biometrics 61:962–972

27. Funk MJ, Westreich D, Chris Wiesen C et al (2011) Doubly robust estimation of causal effects. Am J Epidemiol 173(7):761–767

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.